Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Tesamorelin is FDA-approved for HIV-associated lipodystrophy, with two pooled Phase III RCTs showing a ~15% treatment-effect reduction in visceral adipose tissue over 26 weeks vs. placebo (Falutz et al. 2010, JCEM, PMID 20554713; Falutz et al. 2010, J Acquir Immune Defic Syndr, PMID 20101189). As a GHRH analog it stimulates the pituitary's own pulsatile GH/IGF-1 release rather than replacing GH directly, and it does not suppress the testosterone axis, so no PCT is required. Rated 4, consistent with the other GH secretagogues in this scale (CJC-1295, Ipamorelin, GHRP-2/6, MK-677, Mod GRF), a real, clinically documented step up in GH/IGF-1 exposure, but it works through natural pituitary feedback and its proven benefit is body-composition/visceral-fat-specific rather than a general anabolic/muscle-building effect.
Overview
A GHRH analog FDA-approved for reducing visceral adipose tissue. Particularly effective at targeting stubborn abdominal and visceral fat.
Important Warnings
- •Not for use in patients with active malignancy
- •Contraindicated with hypothalamic-pituitary axis disruption (e.g. pituitary surgery, radiation, or tumors) and known hypersensitivity to tesamorelin
- •Monitor IGF-1 levels during use
- •Can raise blood glucose and new-onset diabetes risk via GH elevation. Monitor fasting glucose/HbA1c, especially in at-risk individuals
- •Visceral fat re-accumulates after discontinuation. Benefit is maintained only while dosing
Purpose & Use Cases
Visceral Fat Reduction
Specifically targets stubborn abdominal and visceral fat stores.
Body Composition
Improves overall body composition with focus on midsection.
Benefits
- Targeted visceral fat loss
- FDA-approved with clinical data
- Improved trunk fat distribution
- Natural GH pattern preservation
- Well-studied safety profile
Good to Know
The only GH secretagogue currently FDA-approved and marketed
Tesamorelin (Egrifta SV / Egrifta WR) is the one peptide in this class with an actively marketed FDA approval and Phase III data, first approved in 2010 to reduce excess visceral abdominal fat in HIV-associated lipodystrophy (sermorelin's branded product, Geref, was also once FDA-approved but was discontinued in 2008). That regulatory pedigree sets it apart from research-chemical GHRH analogs.
GHRH analog: stimulates your own GH
It binds pituitary GHRH receptors to drive pulsatile release of endogenous growth hormone, which raises IGF-1. It does not replace GH the way injected somatropin does, so natural pulsatility and feedback are preserved.
Specifically targets visceral fat
Phase III trials showed roughly a 15% reduction in visceral adipose tissue over 26 weeks versus placebo, its defining, evidence-backed effect. It is also studied for NAFLD/liver fat.
Effect is not permanent
Visceral fat re-accumulates once the drug is stopped. The benefit is maintained only while dosing continues, an honest limitation of GH-driven fat loss generally.
Raises IGF-1, monitor and avoid with cancer
Because it elevates IGF-1 (about 47% of patients exceed +2 SD by 26 weeks), the label warns against use with active malignancy, and IGF-1 should be monitored during use. It also raises new-onset diabetes risk (HbA1c ≥6.5% in ~5% vs. ~1% on placebo, hazard ratio ~3.3), so fasting glucose/HbA1c should be monitored, especially in at-risk users.
No fasting requirement, no PCT
Unlike community protocols for some other GH secretagogues that recommend dosing on an empty stomach, the FDA label for tesamorelin specifies only "once daily" with no meal-timing restriction, and the pivotal trials did not control for food intake around dosing. It does not suppress the testosterone axis, so no PCT is required.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 1.3 – 2 mg/day |
| Intermediate | 1.3 – 2 mg/day |
| Advanced | 1.3 – 2 mg/day |
The original 2010 FDA approval and pivotal trials used 2mg/day (original Egrifta formulation, now discontinued in the US). Current commercial products are reformulated to be bioequivalent at a lower dose: Egrifta SV is FDA-labeled at 1.4mg/day and Egrifta WR (bacteriostatic-water reconstitution) at 1.28mg/day. Compounding-pharmacy and off-label/research-chemical protocols often still use ~2mg/day, mirroring the original trials. No loading phase: dosed once daily from the start. VAT reduction was measured at 26 weeks in the pivotal trials (with further improvement through 52 weeks), so shorter courses are unlikely to show the full documented effect, and the benefit reverses within weeks to months of stopping.
Value for the current EGRIFTA SV/WR formulations, per the FDA label.
Side Effects
Joint Pain
commonArthralgia is one of the most commonly reported adverse reactions, roughly 13% of tesamorelin-treated patients vs. ~11% on placebo in pivotal trials.
Usually mild-to-moderate; may improve with continued use.
Injection Site Reactions
commonErythema, pruritus, or irritation at the injection site, reported in roughly 17% of tesamorelin-treated patients vs. ~6% on placebo over 26 weeks (FDA label pooled Phase 3 data).
Rotate injection sites (typically abdomen) and use proper reconstitution technique.
Peripheral Edema / Fluid Retention
commonGH-driven fluid retention can cause peripheral edema (~6% vs. ~2% on placebo) and, less commonly, carpal-tunnel-like symptoms.
Usually mild and dose-related; report persistent swelling or hand numbness/tingling to a physician.
Elevated Blood Sugar / Increased Diabetes Risk
commonRaises IGF-1 and can worsen glucose control; in pivotal trials, new-onset diabetes (HbA1c ≥6.5%) occurred in ~5% of tesamorelin patients vs. ~1% on placebo (hazard ratio ~3.3).
Monitor fasting glucose and HbA1c periodically, especially in those with pre-existing insulin resistance or diabetes risk factors.
General Mitigation Strategies
Monitor IGF-1 and fasting glucose/HbA1c periodically. Rotate injection sites. Joint pain and fluid retention are usually mild and tend to improve with continued use; report persistent swelling or carpal-tunnel-like symptoms to a physician.
Post Cycle Therapy (PCT)
Does not suppress natural hormone production. No PCT required.
How It Works
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release natural growth hormone. It specifically targets visceral fat reduction.
Fundamentals
Reference on the practices relevant to Tesamorelin: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Tesamorelin - typically run solo at ~1.3-2mg/day for visceral fat
- Tesamorelin + Ipamorelin - GHRH 'on switch' plus a clean GHRP pulse
Legal Status
Prescription only (USA): FDA-approved for HIV lipodystrophy (marketed as Egrifta SV / Egrifta WR).
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Tesamorelin is prohibited at all times under WADA category S2 as a growth hormone-releasing hormone (GHRH) analogue.
References
- Falutz et al. 2010: tesamorelin, pooled analysis of two Phase 3 trials in HIV excess abdominal fat; VAT treatment effect -15.4% (J Clin Endocrinol Metab, PMID 20554713)
- Falutz et al. 2010: tesamorelin RCT in HIV abdominal fat accumulation with safety extension; VAT -10.9% vs placebo (J Acquir Immune Defic Syndr, PMID 20101189)
- EGRIFTA SV (tesamorelin) FDA-approved prescribing information, DailyMed (NIH/NLM)